Results 61 to 70 of about 461 (138)

Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: A Head-to-Head Network Meta-Analysis of Mavacamten and Aficamten

Background: Hypertrophic cardiomyopathy (HCM) is a genetic disorder characterized by myocardial hypercontractility. Mavacamten and aficamten are first-in-class cardiac myosin inhibitors that have demonstrated efficacy in treating obstructive HCM. However,
Imran Saleh, Yenny Dian Andayani, Syamsu Indra, Rukiah Chodilawati, Yuniza   +4 more
core   +1 more source

Integrative Approaches in the Management of Hypertrophic Cardiomyopathy: A Comprehensive Review of Current Therapeutic Modalities

Biomedicines
Hypertrophic cardiomyopathy (HCM) is often associated with left ventricular outflow tract (LVOT) obstruction, which affects a substantial proportion of patients.
Marco Maria Dicorato, Gaetano Citarelli, Francesco Mangini, Rossella Alemanni, Miriam Albanese, Sebastiano Cicco, Cosimo Angelo Greco, Cinzia Forleo, Paolo Basile, Maria Cristina Carella, Marco Matteo Ciccone, Andrea Igoren Guaricci, Ilaria Dentamaro   +12 more
doaj   +1 more source

Issue Information

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 12, Page 1893-1896, December 2025.
wiley   +1 more source

Hypertrophic cardiomyopathy: insights into pathophysiology and novel therapeutic strategies from clinical studies

The Egyptian Heart Journal
Background Hypertrophic cardiomyopathy (HCM) is a frequently encountered cardiac condition worldwide, often inherited, and characterized by intricate phenotypic and genetic manifestations.
Samuel Oluwadare Olalekan, Olalekan Olanrewaju Bakare, Patrick Godwin Okwute, Ifabunmi Oduyemi Osonuga, Muinat Moronke Adeyanju, Victoria Biola Edema   +5 more
doaj   +1 more source

Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy: An Integrated Safety Analysis

European Heart Journal
ABSTRACT BACKGROUND Aficamten is a next-in-class, oral, selective cardiac myosin inhibitor approved for the treatment of obstructive hypertrophic cardiomyopathy (oHCM). A comprehensive understanding of long-term safety is essential to inform clinical use.
Ahmad Masri, Martin S. Maron, Roberto Barriales-Villa, Robert M. Cooper, Perry Elliott, Michael A. Fifer, Pablo Garcia-Pavia, Anjali T. Owens, Scott D. Solomon, Albree Tower-Rader, Camelia Dumitrescu, Justin Godown, Stephen B. Heitner, Daniel L. Jacoby, Stuart Kupfer, Fady I. Malik, Regina Sohn, Jenny Wei, Sara Saberi   +18 more
openaire   +2 more sources

Effect of Aficamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCM

Circulation: Heart Failure
BACKGROUND: Women with obstructive hypertrophic cardiomyopathy often present with a greater burden of disease and worse prognosis. Whether there are sex-related differences in response to aficamten is unknown. METHODS:
Xiaowen Wang, Maria A. Pabon, Tracy T. Makuvire, Reziwanguli Maimaiti, Theodore P. Abraham, Roberto Barriales-Villa, Brian L. Claggett, Caroline J. Coats, Martin S. Maron, Ahmad Masri, Benjamin Meder, Michael E. Nassif, Iacopo Olivotto, Anjali T. Owens, Sara Saberi, Daniel L. Jacoby, Stephen B. Heitner, Stuart Kupfer, Fady I. Malik, Amy Wohltman, Scott D. Solomon, Sheila M. Hegde   +21 more
openaire   +2 more sources

The Efficacy and Safety of Cardiac Myosin Inhibitors Versus Placebo in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials

Introduction: Obstructive hypertrophic cardiomyopathy (oHCM) is a genetic disorder characterized by myocardial hypertrophy, which can obstruct left ventricular outflow.
Nadeem, Samia, MD, Valania, Gregory, MD, Ezenna, Chidubem, MD, Goldsweig, Andrew, MD   +3 more
core   +1 more source

The ODYSSEY-HCM and MAPLE-HCM studies: the role of cardiac myosin inhibitors in hypertrophic cardiomyopathy (obstructive and non-obstructive). [PDF]

Eur Heart J Suppl
Biagini E, Schiavo MA.
europepmc   +1 more source

Evolving strategies in obstructive hypertrophic cardiomyopathy: myosin inhibitors as monotherapy compared with beta-blockers. [PDF]

Heart Fail Rev
Grupper A, Sverdlov AL, Cheema BS, Nasrollahizadeh A, Hosseini K.   +4 more
europepmc   +1 more source

Efficacy and Safety of Mavacamten and Aficamten in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis. [PDF]

Crit Pathw Cardiol
Ibrahim M, Kashif A, Arfin SMW, Mubeen M, Zafar A, Balach R, Ahmed A, Musani MH, Greene SJ, Fonarow GC, Sohail MU.   +10 more
europepmc   +1 more source